Perphenazine Injection

This product is a piperazine derivative of the phenothiazine class, and its pharmacological action is similar to that of chlorpromazine. Its antipsychotic effect is mainly related to its blocking of dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways related to emotional thinking, while its blocking of α-adrenaline receptors in the reticular formation ascending activation system is related to its sedative and tranquilizing effect. It has a strong antiemetic effect, but a weak sedative effect, and can produce more severe extrapyramidal symptoms.

The main ingredient of this product is perphenazine, and its chemical name is: 4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol.

This product is a colorless or slightly yellow clear liquid

It has a good effect on hallucinations, delusions, thinking disorders, apathy, stupor, anxiety and agitation. It is used for schizophrenia or other psychotic disorders. Because of its weak sedative effect, it has little effect on blood pressure. It is suitable for organic mental illness, senile mental disorders and children's aggressive behavior disorders.

For the treatment of schizophrenia, 5-10 mg is injected intramuscularly twice a day. Or 5 mg is injected intravenously once, diluted with sodium chloride injection to 0.5 mg/ml, and the injection speed does not exceed 1 mg per minute. After the patient cooperates, it can be changed to oral administration.

1. Mainly extrapyramidal reactions, such as: tremor, rigidity, drooling, bradykinesia, akathisia, acute dystonia, etc. Long-term and large-scale medication can cause tardive dyskinesia. 2. It can cause an increase in plasma prolactin concentration, and possible related symptoms are: galactorrhea, gynecomastia, menstrual disorders, and amenorrhea. Dry mouth, blurred vision, fatigue, dizziness, tachycardia, constipation, sweating, etc. may occur. 3. Rare adverse reactions include postural hypotension, neutropenia and toxic liver damage. Allergic rash and malignant syndrome are occasionally seen.

Patients with basal ganglia lesions, Parkinson's disease, Parkinson's syndrome, bone marrow suppression, glaucoma, coma, and allergy to phenothiazines.

1. This product can enhance the effect of each other when used in combination with ethanol or central nervous system depressants, especially inhaled general anesthetics or intravenous general anesthetics such as barbiturates. 2. When this product is used in combination with amphetamines, the effect of the latter can be weakened due to the α-adrenaline receptor blocking effect of phenothiazines. 3. This product can reduce oral absorption when used in combination with antacids or antidiarrheal drugs. 4. This product cannot enhance the effect of anticonvulsants when used in combination with anticonvulsants. 5. This product can enhance the effect of each other when used in combination with anticholinergics. 6. When this product is used in combination with epinephrine, the α receptor effect of epinephrine is blocked, and only the β receptor effect is shown, which can cause obvious hypoglycemia and tachycardia.

Keep away from light and store in sealed container.

1ml:5mg

Reyoung Pharmaceutical Co., Ltd.

• Founded in:

  1998-03-20

• Address:

  No. 1, Ruiyang Road, Yiyuan County, Shandong Province

• Tax NO.:

  913703001686121827

• Registered Funds:

  366.74 million yuan

• Website:

  Log in to view

• Email:

  Log in to view